A comparison of two approaches for intraoperative levosimendan administration in cardiac surgical patients with severe left ventricle dysfunction
Background. It is proved that levosimendan administration improves overall outcome and reduces mortality in high risk cardiac patients. However, up to now there is no optimal scheme of its use in intraoperative settings. The aim. To compare two approaches oflevosimendan administration in patients with left ventricle ejection fraction less than 35% who underwent cardiac surgery. Materials and methods. After approval by the local ethics Committee, 40 patients older than 18 years with severe preoperative left ventricular dysfunction (left ventricle ejection fraction less than 35%), who were planned for cardiac surgery operation with cardiopulmonary bypass and cardioplegia were randomly assigned to two groups of 20 patients each. In group 1 (n=20) infusion of levosimendan started intraoperatively after induction of anesthesia, a loading dose of 6 mg/kg with subsequent injection of a dose of 0.1 μg/kg/min for 24 hours. In group 2 (n=20) bolus of levosimendan 24 μg/kg was injected 15 min before aortic clamping. Anesthesia and methods of cardiopulmonary bypass in the groups did not differ. Results. We got the favorable clinical results in a group of “full” levosimendan dose (12.5 mg as a daily infusion with an initial bolus of 6 mg/kg just after the induction of anesthesia) in terms of reduction of the total dose of sympathomimetics and postoperative troponin T level in comparison with the group where levosimendan was administered as a single bolus (24 mg/kg) 15 minutes prior to aortic clamping. Conclusion. Based on these data it can be assumed that the use of prolonged infusion of levosimendan in a dosage of 12.5 mg is preferable to a single bolus 24 μg/kg.
About the authorsPasyuga Vadim V.
Adamopoulos S., Parissis J.T., Iliodromitis E.K. et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am. J. Cardiol. 2006; 98: 102-6.
Giannakoulas G., Giannoglou G., Vassilikos V. et al. Clinical significance of acute neurohormonal response after levosimendan treatment. Am. J. Cardiol. 2006; 98: 1123-4.
Parissis J.T., Karavidas A., Bistola V. et al. Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis. 2008; 197: 278-82.
du Toit E.F., Genis A., Opie L.H., Pollesello P., Lochner A. A role for the RISK pathway and K (ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. Br. J. Pharmacol. 2008; 154: 41-50.
Papp J.G., Pollesello P., Varro A.F., Vegh A.S. Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs. J. Cardiovasc. Pharmacol. Ther. 2006; 11: 129-35.
Cammarata G.A., Weil M.H., Sun S., Huang L., Fang X., Tang W. Levosimendan improves cardiopulmonary resuscitation and survival by K (ATP) channel activation. J. Am. Coll. Cardiol. 2006; 47: 1083-5.
Honisch A., Theuring N., Ebner B., Wagner C., Strasser R.H., Weinbrenner C. Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition. Basic Res. Cardiol. 2009; 105: 155-67.
Jamali I.N., Kersten J.R., Pagel P.S., Hettrick D.A., Warltier D.C. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth. Analg. 1997; 85: 23-9.
Lochner A., Colesky F., Genade S. Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic inotropic response of the myocardium. Cardiovasc. Drugs Ther. 2000; 14: 271-81.
Chen Q., Camara A.K., Rhodes S.S., Riess M.L., Novalija E., Stowe D.F. Cardiotonic drugs differentially alter cytosolic [Ca2+] to left ventricular relationships before and after ischemia in isolated guinea pig hearts. Cardiovasc. Res. 2003; 59: 912-25.
Tritapepe L., De Santis V., Vitale D., Guarracino F., Pellegrini F., Pietropaoli P., Singer M. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br. J. Anaesth. 2009; 102 (2): 198-204.
Григорьев E.В., Торопова Я.Г., Плотников Г.П. и др. Фармакологическая кардиопротекция при реперфузии изолированного сердца. Анестезиол. и реаниматол. 2015; (2): 12-6.
Landoni G., Mizzi A., Biondi-Zoccai G. et al. Reducing mortality in cardiac surgery with levosimendan: A meta-analysis of randomized controlled trials. J. Cardiothorac. Vasc. Anesth. 2010; 24 (1): 51-7.
Greco T., Calabrò M.G., Covello R.D. et al. Bayesian network metaanalysis on the effect of inodilatory agents on mortality. Br. J. Anaesth. 2015; 114 (5): 746-56.
Maharaj R., Metaxa V. Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials. Crit. Care. 2011; 15: R140.
Toller W., Heringlake M., Guarracino F. et al. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. Int. J. Cardiol. 2015; 184: 323-36.
Alvarez J., Baluja A., Selas S. et al. A comparison of dobutamine and levosimendan on hepatic blood flow in patients with a low cardiac output state after cardiac surgery: a randomised controlled study. Anaesth. Intensive Care. 2013; 41: 719-27.
Для цитирования: Pasyuga V.V., Belov S.I., Yusupova E.S., Adzhigaliev R.R., Berezhnoy S.A., Panov O.S., Tarasov D.G., Yavorovsky A.G. A comparison of two approaches for intraoperative levosimendan administration in cardiac surgical patients with severe left ventricle dysfunction. Anesteziologiya i reanimatologiya (Russian journal of Anаеsthesiology and Reanimatology) 2016; 61(5): 334-338. (In Russ.). DOI: http://dx.doi.org/10.18821/0201-7563-2016-61-5-334-338
- Refbacks are not listed
Контент доступен под лицензией Creative Commons Attribution 3.0 License.
ISSN: 0201-7563 (Print)